Recently, several reports have indicated that K-RAS mutations are an important predictor of resistance to cetuximab [13-15] and panitumumab therapy [16] in metastatic colorectal cancer patients and are associated with an unfavourable prognosis. Here, KRAS is linked to metastatic colorectal cancer.